AZD0780 + Placebo
Phase 3Active 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Heterozygous Familial Hypercholesterolaemia
Conditions
Heterozygous Familial Hypercholesterolaemia
Trial Timeline
Jun 10, 2025 → Jan 4, 2027
NCT ID
NCT07000136About AZD0780 + Placebo
AZD0780 + Placebo is a phase 3 stage product being developed by AstraZeneca for Heterozygous Familial Hypercholesterolaemia. The current trial status is active. This product is registered under clinical trial identifier NCT07000136. Target conditions include Heterozygous Familial Hypercholesterolaemia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (5)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07423598 | Phase 1 | Recruiting |
| NCT07000136 | Phase 3 | Active |
| NCT07000357 | Phase 3 | Recruiting |
| NCT07000123 | Phase 3 | Active |
| NCT06173570 | Phase 2 | Completed |
Competing Products
18 competing products in Heterozygous Familial Hypercholesterolaemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Anacetrapib + Placebo for anacetrapib | Merck | Phase 3 | 77 |
| Enlicitide Decanoate + Placebo | Merck | Phase 2/3 | 65 |
| Inclisiran | Novartis | Phase 3 | 77 |
| Inclisiran + Placebo | Novartis | Phase 3 | 77 |
| Fluvastatin | Novartis | Phase 3 | 77 |
| Inclisiran + Placebo | Novartis | Phase 3 | 77 |
| Evolocumab + Placebo | Amgen | Phase 3 | 76 |
| Bococizumab (PF-04950615;RN316) | Pfizer | Phase 3 | 76 |
| Atorvastatin + Atorvastatin | Pfizer | Phase 1 | 32 |
| IBI306 + placebo | Innovent Biologics | Phase 3 | 76 |
| Lumacaftor Plus Ivacaftor Combination + Ivacaftor | Vertex Pharmaceuticals | Phase 3 | 76 |
| LMT (atorvastatin, simvastatin, or rosuvastatin) + alirocumab + Placebo | Sanofi | Phase 3 | 76 |
| Placebo + Alirocumab | Sanofi | Phase 3 | 76 |
| Praluent | Sanofi | Approved | 84 |
| AK102 + Placebo + Statins and/or Ezetimibe | Akeso | Phase 2 | 51 |
| lerodalcibep | Medpace | Phase 3 | 74 |
| mipomersen sodium + placebo | Ionis Pharmaceuticals | Phase 3 | 74 |
| MGL-3196 (resmetirom) + Placebo | Madrigal Pharmaceuticals | Phase 2 | 49 |